These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 1353747)

  • 1. [Compliance in therapy of schizophrenic patients with neuroleptics--an overview].
    Mayer C; Soyka M
    Fortschr Neurol Psychiatr; 1992 Jun; 60(6):217-22. PubMed ID: 1353747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic treatment with neuroleptics. II: Subjective mechanisms of effect, compliance and consequences for treatment strategy].
    Krausz M; Sorgenfrei T
    Psychiatr Prax; 1991 Jan; 18(1):14-20. PubMed ID: 1674155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Compliance problems in treatment of schizophrenic patients].
    Barnas C; Hummer M; Fleischhacker WW
    Wien Med Wochenschr; 1998; 148(11-12):281-3. PubMed ID: 9746971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The problem of drug compliance in schizophrenic patients].
    Albus M
    Psychiatr Prax; 1995 Nov; 22(6):221-2. PubMed ID: 8570750
    [No Abstract]   [Full Text] [Related]  

  • 5. [Patient modified medication: how do schizophrenic patients manage their neuroleptics?].
    Hornung WP; Buchkremer G; Redbrake M; Klingberg S
    Nervenarzt; 1993 Jul; 64(7):434-9. PubMed ID: 8103569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapeutic treatment with neuroleptics. I: State of research on mechanisms of action, effectiveness and compliance in treatment of psychoses].
    Krausz M; Sorgenfrei T
    Psychiatr Prax; 1991 Jan; 18(1):9-13. PubMed ID: 1674156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adherence to neuroleptic treatment of schizophrenic patients].
    Blondiaux I; Alagille M; Ginestet D
    Encephale; 1988; 14(6):431-8. PubMed ID: 2906607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride.
    Linden M; Scheel T; Eich FX
    J Psychopharmacol; 2006 Nov; 20(6):815-23. PubMed ID: 16401647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Can psycho-education of chronic schizophrenic patients have a short-term effect on drug-related attitude and behavior?].
    Hornung WP; Franzen U; Lemke R; Wiesemann C; Buchkremer G
    Psychiatr Prax; 1993 Jul; 20(4):152-4. PubMed ID: 8103230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Negative vs. positive therapy expectations and compliance vs. noncompliance].
    Linden M
    Psychiatr Prax; 1987 Jul; 14(4):132-6. PubMed ID: 2887002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications].
    Misdrahi D; Llorca PM; Lançon C; Bayle FJ
    Encephale; 2002; 28(3 Pt 1):266-72. PubMed ID: 12091789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment.
    Löffler W; Kilian R; Toumi M; Angermeyer MC
    Pharmacopsychiatry; 2003 May; 36(3):105-12. PubMed ID: 12806568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depot neuroleptics: the relevance of psychosocial factors--a United States perspective.
    Hogarty GE
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):36-42. PubMed ID: 6143746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of partial compliance.
    Marder SR
    J Clin Psychiatry; 2003; 64 Suppl 16():3-9. PubMed ID: 14680412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonadherence to antipsychotic treatment in patients with schizophrenic disorders.
    Svestka J; Bitter I
    Neuro Endocrinol Lett; 2007 Feb; 28 Suppl 1():95-116. PubMed ID: 17262005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Psychological effects of previous treatment experiences with neuroleptics].
    Bossert S; Dose M; Emrich HM; Garcia D; Junker M; Raptis K; Weber MM
    Nervenarzt; 1990 May; 61(5):301-5. PubMed ID: 1972785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards the improvement of compliance: the significance of psycho-education and new antipsychotic drugs.
    Gaebel W
    Int Clin Psychopharmacol; 1997 Feb; 12 Suppl 1():S37-42. PubMed ID: 9179642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New generation antipsychotic drugs and compliance behaviour.
    Voruganti LP; Baker LK; Awad AG
    Curr Opin Psychiatry; 2008 Mar; 21(2):133-9. PubMed ID: 18332660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients.
    Glazer WM; Ereshefsky L
    J Clin Psychiatry; 1996 Aug; 57(8):337-45. PubMed ID: 8752015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Medication-related attitudes of chronic schizophrenic patients. A follow-up study after psycho-educational intervention].
    Hornung WP; Schonauer K; Feldmann R; Mönking HS
    Psychiatr Prax; 1998 Jan; 25(1):25-8. PubMed ID: 9530765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.